Analysts expect BioTime, Inc. (NASDAQ:BTX) to announce $710,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for BioTime’s earnings, with the highest sales estimate coming in at $1.23 million and the lowest estimate coming in at $100,000.00. BioTime posted sales of $2.55 million during the same quarter last year, which suggests a negative year over year growth rate of 72.2%. The business is expected to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that BioTime will report full-year sales of $3.28 million for the current financial year, with estimates ranging from $1.20 million to $5.13 million. For the next year, analysts anticipate that the business will report sales of $4.13 million, with estimates ranging from $3.50 million to $5.18 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow BioTime.

BioTime (NASDAQ:BTX) last issued its earnings results on Thursday, May 9th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The firm had revenue of $0.93 million during the quarter, compared to the consensus estimate of $0.66 million.

A number of analysts recently issued reports on BTX shares. Dawson James reiterated a “buy” rating on shares of BioTime in a research note on Thursday, February 7th. HC Wainwright reiterated a “buy” rating on shares of BioTime in a research note on Thursday, February 21st.

Shares of BTX traded down $0.02 during mid-day trading on Friday, hitting $1.11. The stock had a trading volume of 1,651 shares, compared to its average volume of 872,433. BioTime has a 52 week low of $0.66 and a 52 week high of $2.81.

BioTime Company Profile

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Recommended Story: Is a Roth IRA right for you?

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with's FREE daily email newsletter.